APLS Jan 2026 60.000 call
| Previous close | 11.30 |
| Open | 11.30 |
| Bid | 7.40 |
| Ask | 10.20 |
| Strike | 60.00 |
| Expiry date | 2026-01-16 |
| Day's range | 11.30 - 11.30 |
| Contract range | N/A |
| Volume | |
| Open interest | 37 |
ZacksApellis Pharmaceuticals, Inc. (APLS) Reports Q1 Loss, Tops Revenue Estimates
Apellis Pharmaceuticals (APLS) delivered earnings and revenue surprises of 0% and 7.36%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewswireApellis Pharmaceuticals Reports First Quarter 2024 Financial Results
Generated $172.3 million in 1Q 2024 revenues, including $163.1 million in U.S. net product sales $137.5 million for SYFOVRE® (pegcetacoplan injection) $25.6 million for EMPAVELI® (pegcetacoplan) Anticipates CHMP opinion for pegcetacoplan in GA no later than July 2024On track to report topline Phase 3 data with systemic pegcetacoplan in C3G / IC-MPGN in mid-2024Cash and cash equivalents of $325.9 million as of March 31, 2024; projected revenues and cash expected to be sufficient to fund operation
- GlobeNewswire
Apellis Pharmaceuticals to Host a Fireside Chat at the Bank of America Securities Healthcare Conference
WALTHAM, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a fireside chat at the Bank of America Securities Healthcare Conference on Tuesday, May 14, 2024, at 8:00 a.m. PT. The live conference webcast will be posted on the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcast will be available for approximately 90 days following the event. About ApellisA
